- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02355704
Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney
Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney Transplantation in Vivo
Renal Insufficiency is a priority disease in health system, which may require renal replacement therapy based on renal transplantation, which is considered as therapy of choice. During the procedure of renal transplantation, the graft could be damaged by ischemia-reperfusion which generates complications in its function.
Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in renal transplantation.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Objective: Evaluate anti-inflammatory effect of atorvastatin on renal graft in living donor transplantation.
Material and methods: Controlled, double-blind clinical trial with posterior following for 12 months. Composed by 48 patients, randomized manner, realized at the Transplant Department of Western Medical Center, Mexican Institute of Social Security. Universe was patients accepted as kidney donors. Patients were randomized in two groups (study or control) the intervention was implemented 4 weeks before kidney transplant. Previous surgical procedure, in a blood sample, C-Reactive Protein (C-RP) and laboratory control were measured. During surgical procedure, a biopsy was obtained to measure IL-6 and tumoral necrosis factor alpha by immunohistochemistry. 24 hours after surgical procedure, 3 and 12 months of following, kidney function, complications and graft survival were registered. During surgical procedure, 3 months and 12 months of following, biopsies were obtain to performed histopathological analysis of scale of Banff
The statistical analysis was performed according to the nature of variables, for continuous data using measures of central tendency and dispersion and for the qualitative data with frequencies and percentages.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Jalisco
-
Guadalajara, Jalisco, Messico, 44340
- Western Medical Center, Mexican Institute of Social Security
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Accepted as kidney donor
- Voluntary participation
- Informed consent accepted
- 85% fulfillment of atorvastatin treatment
Exclusion Criteria:
- Hypersensibility to Atorvastatin
- Smoking
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Atorvastatin
22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
|
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation.
Previous surgical procedure controls were performed
Altri nomi:
|
Comparatore placebo: Placebo
22 patients received oral placebo 40 mg 1 time for day for 4 weeks
|
Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation.
Previous surgical procedure were performed
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
C-Reactive Protein evolution in donors
Lasso di tempo: Basal and 4 weeks later
|
C-Reactive Protein was measured when patients (donors) were accepted in the study and 4 weeks later.
The last blood sample was taken the day of surgical procedure.
|
Basal and 4 weeks later
|
Kidney graft rejection using scale of BANFF
Lasso di tempo: Basal, 3 months and 12 months
|
During surgical procedure and before organ transplantation, basal biopsy was obtain.
In the following at 3 and 12 months after kidney transplantation, were performed the other two biopsy.
Alterations between groups were registered.
|
Basal, 3 months and 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Kidney function evolution after transplant
Lasso di tempo: 24 hours, 3 months and 12 months
|
In blood samples, after kidney transplantation, creatinine and urea were measured.
Differences in evolution and alteration between the 2 groups were registered
|
24 hours, 3 months and 12 months
|
Interleukin and tumor necrosis factor alpha.
Lasso di tempo: Basal
|
During surgical procedure and before organ transplantation, the biopsy was obtain to measure interleukin 6 and tumor necrosis factor alpha, observing alteration between groups.
|
Basal
|
Complications
Lasso di tempo: 24 hours, 3 months and 12 months
|
During surgical procedure, any kind of complication was registered, the same right after surgery and in the following.
|
24 hours, 3 months and 12 months
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Clotilde Fuentes-Orozco, PhD, Instituto Mexicano del Seguro Social
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2011-1301-78
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Insufficienza renale
-
National Cancer Institute (NCI)NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group BCompletatoCarcinoma a cellule renali a cellule chiare | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti, Canada, Porto Rico
-
National Cancer Institute (NCI)TerminatoCarcinoma a cellule renali a cellule chiare | Carcinoma a cellule renali metastatico | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Cancro a cellule renali in stadio II AJCC v7 | Stadio I Renal Cell Cancer AJCC v6 e v7Stati Uniti
Prove cliniche su Atorvastatin
-
Peking Union Medical College HospitalReclutamentoFemmina di cancro al senoCina
-
Dong-A ST Co., Ltd.Sconosciuto
-
University Hospital Inselspital, BernePharmaPart; Viollier AG, Basel, SwitzerlandCompletatoSclerosi multipla recidivante-remittenteSvizzera
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Sconosciuto
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR); BiovaloremReclutamentoTumore del pancreas | Cancro metastatico | Adenocarcinoma duttale pancreatico | Cancro al pancreasCanada